Imjudo (tremelimumab-actl) injection

Imjudo is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated: in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. <a id="